Saffo S, Kaplan DE, Mahmud N, et al. - By conducting a propensity score matched intention-to-treat analysis, researchers assessed if sodium-glucose cotransporter 2 inhibitors (SGLT2i) can offer a reduction in the incidence of ascites and death over a span of 36 months in patients suffering from cirrhosis and diabetes mellitus. They utilized electronic health data from Veterans Affairs hospitals in the United States, and analyzed veterans receiving metformin who subsequently took either SGLT2i or dipeptidyl peptidase-4 inhibitors. They analyzed 423 matched pairs (in total, 846 patients). Findings indicate that an improved survival may be conferred by SGLT2i, vs dipeptidyl peptidase-4 inhibitors, in patients with cirrhosis who need additional pharmacotherapy for diabetes mellitus beyond metformin, but there is need for confirmatory studies.